News

The West Australian – Proteomics JV developing blood test for oesophageal cancer

The partnership between the ASX-listed Proteomics and QIMR Berghofer will see Proteomics deploy its Promarker platform to initially analyse and then clinically validate a panel of biomarkers, commonly referred to as protein ‘fingerprints’ in blood, which QIMR Berghofer researchers discovered were associated with the early stages of the disease.

The ability to apply a blood test to detect the cancer would dramatically reduce the risks associated with current detections methods which principally involve an invasive endoscopy being passed down a patient’s throat.

Article: Proteomics JV developing blood test for oesophageal cancer

Print article:

Subscribe
  • This field is for validation purposes and should be left unchanged.